CRAIG T. SMITH, P.T.
Physical Therapy at North River Dr, Spokane, WA

License number
Washington PT00000708
Category
Restorative Service Providers
Type
Physical Therapist
Address
Address 2
322 NORTH North River Dr, Spokane, WA 99201
PO Box 34584, Seattle, WA 98124
Phone
(509) 324-6464
(509) 241-7349
(509) 241-7628 (Fax)

Professional information

Craig Smith Photo 1

Business Operations Manager At Safeco Insurance

Position:
Business Operations Manager at Safeco Insurance, Business Operations Manager at Liberty Mutual
Location:
Greater Seattle Area
Industry:
Insurance
Work:
Safeco Insurance since Mar 1999 - Business Operations Manager Liberty Mutual since 1999 - Business Operations Manager Gart Sports 1993 - 1999 - Store Manager
Education:
Central Washington University 1980 - 1984
Bachelor of Science (B.S.), Business, Management, Marketing, and Related Support Services
Skills:
Property & Casualty Insurance, Insurance, General Insurance, Underwriting, Process Improvement, Operations Management, Budgets


Craig Smith Photo 2

Craig Smith - Seattle, WA

Work:
VolkerFitzpatrick
o Lead Quantity Surveyor
Hadsphaltic International Limited
Senior Quantity Surveyor
HBG Construction Limited
Project Quantity Surveyor
Mansell Construction Services Ltd
Assistant QS
John Laing Construction
Education:
University of Wolverhampton
Bachelor of Science in Quantity Surveying


Craig Smith Photo 3

Information Technology And Services Professional

Location:
Greater Seattle Area
Industry:
Information Technology and Services


Craig Smith Photo 4

Immunomodulatory Compositions And Uses Therefor

US Patent:
2009011, May 7, 2009
Filed:
Oct 6, 2008
Appl. No.:
12/246291
Inventors:
Craig A. Smith - Seattle WA, US
Steven Wiley - Seattle WA, US
Ajamete Kaykas - Seattle WA, US
Jalal Vakili - Seattle WA, US
Peter Probst - Seattle WA, US
Assignee:
VIRAL LOGIC SYSTEMS TECHNOLOGY CORPORATION - SEATTLE WA
International Classification:
A61K 39/395, C07K 16/00, A61P 37/02
US Classification:
4241361, 5303891, 53038822, 5303873, 5303911, 4241301
Abstract:
The poxvirus proteins designated A41L and 130L bind to three receptor-like protein tyrosine phosphatases (RPTP), leukocyte common antigen related protein (LAR), RPTP-δ, and RPTP-σ, that are present on the cell surface of immune cells. When a host is infected with the poxvirus, binding of A41L to cell surface proteins on the host cells results in suppression of the immune response. The present invention provides agents such as antibodies, and antigen-binding fragments thereof, small molecules, aptamers, small interfering RNAs, and peptide-IgFc fusion polypeptides that interact with one or more of LAR, RPTP-δ, and RPTP-σ expressed by immune cells or interact with a polynucleotide encoding the RPTP. Also provided are RPTP Ig domain oligomers and Fc fusion polypeptides. Such agents are useful for treating an immunological disorder in a subject according to the methods described herein.


Craig Smith Photo 5

Dna Encoding Tumor Necrosis Factor-.Alpha. And -.Beta. Receptors

US Patent:
5395760, Mar 7, 1995
Filed:
May 10, 1990
Appl. No.:
7/523635
Inventors:
Craig A. Smith - Seattle WA
Raymond G. Goodwin - Seattle WA
M. Patricia Beckmann - Poulsbo WA
Assignee:
Immunex Corporation - Seattle WA
International Classification:
A61K 4505, C12P 2106, C12N 1500, C07H 1700
US Classification:
4352401
Abstract:
Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.


Craig Smith Photo 6

Cytokine Designated 4-Ibb Ligand

US Patent:
5674704, Oct 7, 1997
Filed:
May 6, 1994
Appl. No.:
8/236918
Inventors:
Raymond G. Goodwin - Seattle WA
Craig A. Smith - Seattle WA
Mark R. Alderson - Bainbridge Island WA
Assignee:
Immunex Corporation - Seattle WA
International Classification:
C12N 1512, C12N 1563, C07K 14705
US Classification:
435 691
Abstract:
Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.


Craig Smith Photo 7

Cd47 Related Compositions And Methods For Treating Immunological Diseases And Disorders

US Patent:
8377448, Feb 19, 2013
Filed:
Jan 14, 2010
Appl. No.:
12/687334
Inventors:
Craig A. Smith - Seattle WA, US
Steven Wiley - Seattle WA, US
Ajamete Kaykas - Seattle WA, US
Peter Probst - Seattle WA, US
Assignee:
The Board of Trustees of the Leland Standford Junior University - Palo Alto CA
International Classification:
A61K 39/00
US Classification:
4241851, 4241921, 530300, 530810
Abstract:
Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.


Craig Smith Photo 8

Fusion Proteins Comprising Tumor Necrosis Factor Receptor

US Patent:
2006027, Dec 7, 2006
Filed:
Jun 13, 2006
Appl. No.:
11/451450
Inventors:
Craig Smith - Seattle WA, US
International Classification:
A61K 38/17, C07H 21/04, C12P 21/06, C07K 14/715
US Classification:
435069100, 435320100, 435325000, 530350000, 514012000, 536023500
Abstract:
Fusion proteins having a tumor necrosis factor receptor (TNF-R) polypeptide and at least one additional polypeptide covalently fused thereto and selected from an interleukin-1 receptor (IL-1R) and a second TNF-R polypeptide. The receptor polypeptides are preferably fused together by a peptidyl linker. Suitable fusions include, for example, TNF-R-linker-TNF-R; TNF-R-linker-IL-1R; and TNF-R-linker-TNF-R-linker-IL-1R molecules.


Craig Smith Photo 9

Dna Sequences Encoding Granulocyte-Colony Stimulating Factor Receptors

US Patent:
5422248, Jun 6, 1995
Filed:
Jan 15, 1993
Appl. No.:
8/006183
Inventors:
Craig A. Smith - Seattle WA
Alf D. Larsen - Seattle WA
John E. Sims - Seattle WA
Benson M. Curtis - Seattle WA
Assignee:
Immunex Corporation - Seattle WA
International Classification:
C12N 1500, C12N 1511, C12N 1512
US Classification:
435 691
Abstract:
Mammalian granulocyte-colony stimulating factor (G-CSF) receptor proteins, DNAs and expression vectors encoding mammalian G-CSF receptors, and processes for producing mammalian G-CSF receptors as products of recombinant cell culture, are disclosed.


Craig Smith Photo 10

Methods For Treating Progressive Multiple Sclerosis

US Patent:
2012022, Sep 6, 2012
Filed:
Mar 7, 2012
Appl. No.:
13/414698
Inventors:
Craig Smith - Seattle WA, US
Peter S. Chin - San Francisco CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61P 25/00
US Classification:
4241351, 4241731, 4241331, 4241421
Abstract:
The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.